Case Study: Several stakeholders have engaged the services of CMOs to cater to the complexities rela

Rising complexities related to handling and administration of novel / advanced therapeutic options, have caused many device developers to outsource certain aspects of their businesses to contract service providers. Moreover, development process of drug delivery devices, such as high-volume injectors, involves multiple components (including electronic and mechanical modules), which need to have an appropriate design / size and user interface quality. Currently, close to nearly 30 players across the globe claim to offer manufacturing services to the developers of wearable injectors. These services are related to manufacturing of primary drug containers, adhesive materials or infusion sets / accessories for large volume wearable injectors. In addition, close to 70% of the companies offer adhesive materials, closures, injection moldings, infusion sets and other tools for wearable devices, such as injection needles.

Majority of these (37%) are mid-sized companies (201-1,000 employees), followed by 25% large companies (1,001-10,000 employees) and 21% small-sized companies (less than 200 employees). Further, this domain features the presence of 4 very large firms; examples include (in alphabetical order, headquartered in US) Battelle and SMC.

It is worth highlighting that, most of the players are headquartered in North America (50%) followed by Europe (42%). It is interesting to note that all the North American players are headquartered in US. Within Europe, Switzerland and Germany emerged as a key hub of contract manufacturers, having close to four players each.

In fact, in an interview with the chief executive officer of a small-sized medical device company, he stated that "Currently many drug developers are collaborating with device manufacturers in order to design custom delivery solutions for the proprietary products of the former entities. I am lead to believe that this is going to become the norm in the future. "

The "Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices" report features an extensive study of the current market landscape and the likely future evolution of these self-injection devices, over the next ten years. It specifically lays emphasis on the emergence of patient-centric, convenient, cost-effective and user-friendly wearable drug delivery solutions that are capable of administering large volumes of a drug subcutaneously, in the home-care setting. Amongst other elements, the report includes:

• An overview of current market landscape of the large volume wearable injectors available for delivery of insulin and non-insulin drugs, providing information on status of development and device specifications, such as type of device (patch pump / injector and infusion pump / injector), type of dose administered (basal, bolus and others), route of administration (subcutaneous and others), mode of injection (needle, needle / cannula and needle / catheter), storage capacity of the device, actuation mechanism (electromechanical, rotary pump, cell / expanded battery, pressurized gas, osmotic pressure and others), usability (disposable and reusable), availability of prefilled drug reservoir and availability of device connectivity. The report also features additional information on availability of prefilled insulin cartridges, availability of continuous glucose monitoring / blood glucose monitoring (CGM / BGM) systems, availability of Automated Insulin Delivery feature and type of remote control features (control within device / personal diabetes manager (PDM) / smartphone) in the insulin delivery devices.
• A detailed competitiveness analysis of large volume wearable injectors based on various relevant parameters, such as supplier power (based on the experience / expertise of the developer) and product specifications (type of device, type of dose, storage capacity of the device, usability, route of administration, connectivity and availability of a continuous glucose monitoring / blood glucose monitoring (CGM / BGM) systems (in case of insulin devices).

Roots Analysis provides market research and consulting in the pharmaceutical industry. Focussed on providing an informed and impartial view on key issues facing the industry, our research is primarily driven by an in-depth analysis.